Article: Nicotinamide Riboside Protects Kidneys after Heart Attack: Preclinical Findings

PrevNext
Cardiovascular Disease Cardiovascular Health Kidney Disease Kidney Health Preclinical

Nicotinamide Riboside Protects Kidneys after Heart Attack: Preclinical Findings

Synopsis

Cardiorenal syndrome type 1 occurs when acute kidney injury (AKI) develops after sudden heart problems like a heart attack (MI), increasing the risk of death. This study tested whether nicotinamide riboside (NR), a precursor of NAD+, could help protect the kidneys after MI. In mice, MI reduced heart NAD+ levels, but NR treatment for 4–7 days did not improve heart function. However, NR improved kidney function, reduced cell death, and protected kidney tissue, likely by increasing NAD+ levels through NAMPT in kidney cells, especially in the distal tubules. These results suggest that NR may help prevent kidney damage after a heart attack.

Journal

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Share

Read more

Cardiovascular Disease

NMN and NR Improve Lipid Metabolism but Promote Atherosclerosis in ApoE-Knockout Mice: Preclinical Findings

Synopsis Supplementation with nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) raised NAD+ levels and produced clear metabolic benefits in mice, including reduced body weight, lowe...

Read more
Kidney Disease

Nicotinamide Riboside Protects Against Chronic Kidney Disease by Boosting Metabolism: Preclinical Findings

SynopsisChronic kidney disease (CKD) impairs kidney metabolism, including fatty acid breakdown, and is linked to low NAD+ levels. This study tested nicotinamide riboside (NR), a precursor of NAD+, ...

Read more